uniQure (NASDAQ:QURE) Shares Down 7.4% Following Analyst Downgrade

uniQure N.V. (NASDAQ:QURE)’s share price fell 7.4% on Wednesday after Wells Fargo & Company lowered their price target on the stock from $80.00 to $60.00. Wells Fargo & Company currently has an overweight rating on the stock. uniQure traded as low as $28.80 and last traded at $28.5570. 1,760,884 shares were traded during trading, a decline of 21% from the average session volume of 2,229,264 shares. The stock had previously closed at $30.84.

Other equities analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, October 8th. Royal Bank Of Canada dropped their target price on uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research report on Monday, November 3rd. Guggenheim increased their price objective on shares of uniQure from $28.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Cantor Fitzgerald boosted their target price on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. Finally, The Goldman Sachs Group dropped their price target on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.42.

Insiders Place Their Bets

In related news, Director Robert Gut sold 31,434 shares of uniQure stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84. Following the completion of the sale, the director owned 40,145 shares of the company’s stock, valued at $1,094,352.70. The trade was a 43.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 226,316 shares of the company’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the completion of the sale, the chief executive officer owned 651,454 shares in the company, valued at $27,009,282.84. The trade was a 25.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 314,560 shares of company stock valued at $12,362,568. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in QURE. Private Trust Co. NA purchased a new stake in uniQure during the 3rd quarter worth approximately $28,000. Jones Financial Companies Lllp grew its stake in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the period. Tower Research Capital LLC TRC raised its holdings in uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 5,538 shares during the period. KLP Kapitalforvaltning AS acquired a new position in uniQure during the 2nd quarter worth about $117,000. Finally, Teacher Retirement System of Texas acquired a new stake in uniQure in the 2nd quarter valued at about $151,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Down 6.7%

The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. The firm has a fifty day moving average of $42.55 and a 200 day moving average of $24.50. The stock has a market cap of $1.58 billion, a PE ratio of -7.33 and a beta of 0.59.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, equities research analysts anticipate that uniQure N.V. will post -3.75 EPS for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.